Fluticasone Propionate And Salmeterol Powder
Product Images NDC 50090-4214

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 50090-4214). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure of the active ingredients fluticasone propionate and salmeterol, depicted as molecular diagrams showing rings, bonds, and functional groups characteristic of these compounds used in respiratory inhalation powder formulations.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure diagram showing the molecular composition of the active ingredients fluticasone propionate and salmeterol, components of the respiratory inhalation powder product Fluticasone Propionate and Salmeterol DISKUS.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

A line graph depicting the percentage change in FEV1 over 12 weeks and at the endpoint for four groups: fluticasone propionate/salmeterol 100/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. Data points show trends with fluticasone propionate/salmeterol combination consistently showing the highest improvement.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

A line graph depicting the percentage change in FEV1 over a 12-hour period post-dose from baseline on Day 1. The graph compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The y-axis shows % change in FEV1, while the x-axis represents hours after dosing.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

A line graph showing the percentage change in FEV1 relative to Day 1 baseline over a 12-hour period. It compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily (N=73), Salmeterol 50 mcg twice daily (N=49), Fluticasone propionate 100 mcg twice daily (N=65), and Placebo (N=26). The vertical axis represents % change in FEV1, and the horizontal axis shows hours from baseline to 12 hours.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph depicting the percentage change in FEV1 (lung function) over 24 weeks comparing three groups: Fluticasone propionate/salmeterol 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph shows baseline FEV1 values and the number of patients at various time points for each group.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line chart showing percent change in FEV1 over 24 weeks for three groups: fluticasone propionate/salmeterol 250/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The chart includes baseline FEV1 values and sample sizes at various time points. The fluticasone propionate/salmeterol group shows the highest increase in FEV1.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustration of the Fluticasone Propionate and Salmeterol DISKUS inhaler showing labeled parts: outer case, mouthpiece, lever, thumb grip, and counter. The label on the inhaler indicates a 60-blister package with 100 mcg fluticasone propionate and 50 mcg salmeterol powder for inhalation.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

Illustration showing a person holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with an arrow indicating the direction to slide the lever or open the device for use. The image demonstrates proper handling of the respiratory powder inhalation device.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional diagram showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. The image illustrates the action of sliding the inhaler cover to the side, indicated by an arrow, as part of the device's use process for respiratory powder inhalation.*

FDA Label Image

Ifu Figure D (Fp Sal Spl Graphic 11)

Black and white photo of a woman demonstrating the use of a Fluticasone Propionate and Salmeterol DISKUS inhaler. She holds the DISKUS device close to her mouth, appearing to be in the process of inhalation through the respiratory powder inhalation delivery system.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

An instructional illustration showing a woman using a Fluticasone Propionate and Salmeterol DISKUS inhaler for respiratory powder administration. The image demonstrates proper inhalation technique by holding the device to the mouth.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with an arrow pointing left, indicating the direction to slide or open the device for use.*

FDA Label Image

Ifu Figure G (Fp Sal Spl Graphic 14)

An illustration showing a woman demonstrating an inhalation technique by exhaling forcefully into a sink. A glass of water is placed nearby. This instructional diagram likely depicts proper breathing or device use related to respiratory inhalation medication.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder, 100 mcg/50 mcg strength. The image shows a black, curved powder inhaler device labeled for 50 blisters, with dosage and usage information prominently displayed on the front label. The labeler is A-S Medication Solutions.*

FDA Label Image

Label Image (Lbl500904214)

Fluticasone Propionate and Salmeterol DISKUS label showing active ingredients fluticasone propionate and salmeterol inhalation powder. Strength is 500 mcg of fluticasone propionate and 50 mcg of salmeterol per blister. The label indicates storage instructions to keep between 15 and 30 degrees C and includes packaging details of a foil strip containing 60 blisters. Labeler is A-S Medication Solutions, Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.